Skip to content
Triangle logo TriangleGet started
← Study library

NCT01533207 · REGISTRY CONDITION SEARCH

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
TERMINATED
Registry last update
2020-04-28

This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Who Experienced Death

→

outcome · POSTED

Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

→

outcome · POSTED

Number of Participants With Recurrence

→

outcome · NOT POSTED

Univariate and Multi-variable Prognostic Significance of Baseline Clinical, Pathologic, or Demographic Factors

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients with high-risk uterine leiomyosarcoma (LMS), Federation of Gynecology and Obstetrics (FIGO) stage I (confined to corpus +/- cervix); patients with known uterine serosa involvement are not eligible; patients should have had, at least, a complete hysterectomy (including removal of the cervix); bilateral salpingo-oophorectomy is not required * Institutional pathology review calls the uterine leiomyosarcoma ?high grade? * Additionally, if the pathology report indicates a mitotic rate, the mitotic rate should be greater than or equal to 5 mitoses/10 high-power field * All patients must be no longer than 12 weeks (3 months) from surgical resection of cancer at the time of enrollment on study; if a patient requires a second operation to complete her surgery, i.e., trachelectomy to remove the cervix and/or bilateral salpingo-oophorectomy (BSO), the 12 weeks may be counted from the time of the second operation * Patients who had a ?morcellation? hysterectomy procedure that involved morcellation within the peritoneal cavity are eligible IF a second operation is performed and biopsies from the second procedure show no evidence of leiomyosarcoma * All patients must have no evidence of persistent or metastatic disease as documented by a post-resection computed tomography (CT) of the chest/abdomen/pelvis or by CT chest + magnetic resonance imaging (MRI) abdomen/pelvis; the post-resection imaging studies should be performed within 4 weeks of registration on study * Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL (ANC \>= 1.5 x 10\^9/liter \[L\]) * Platelets greater than or equal to 100,000/mcL (platelets \>= 100 x 10\^9/L) * Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L) * Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN) * Bilirubin\* within normal range * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\])\* and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\])\* less than or equal to 2.5 times ULN * Alkaline phosphatase\* less than or equal to 2.5 x ULN * \* Patients with a history of Gilbert?s syndrome may be eligible provided total bilirubin is less than or equal to 1.5 x ULN and the AST, ALT, and alkaline phosphatase meet the criteria detailed * Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 * Patients with Gynecologic Oncology Group (GOG) performance status of 0 or 1 OR Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 OR Karnofsky performance status (PS) \>= 80% * Patients who have met the pre-entry requirements specified * Patients must have signed an approved informed consent * Patients participating through United States (U.S.) sites must sign an approved and authorization permitting release of personal health information * Patients should be free of active infection requiring antibiotics (with the exception of an uncomplicated urinary tract infection \[UTI\]) Exclusion Criteria: * Patients who have had prior therapy with docetaxel, gemcitabine hydrochloride, or doxorubicin hydrochloride at any time in their history * Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are ineligible if there is any evidence of other malignancy being present within the last five years; patients are also ineligible if their previous cancer treatment contraindicates this protocol therapy * Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80 * Patients with GOG performance status of 2, 3 or 4; or ECOG performance status of 2, 3 or 4 * Patients who are breast-feeding * Patients with a known history of congestive heart failure or cardiac ejection fraction \< 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment * Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction \< 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen I * Patients with a history of prior whole pelvic radiation * Concurrent treatment with hormone replacement therapy is permitted at the discretion of the treating physician; patients who have been taking hormonal/hormone blocking agents for breast cancer or breast cancer prevention or other indication are eligible; use of anti-hormonal agents (tamoxifen, medroxyprogesterone, aromatase inhibitors) is permitted at the discretion of the treating physician; documentation of concurrent medications is required * Patients with recurrent uterine LMS * Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible * Patients with gross residual or metastatic tumor findings following complete surgical treatment for uterine LMS
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
    intervention Names
    1. Drug: Docetaxel
    2. Drug: Doxorubicin Hydrochloride
    3. Biological: Filgrastim
    4. Drug: Gemcitabine Hydrochloride
    5. Biological: Pegfilgrastim
    label
    Arm I (chemotherapy)
    type
    EXPERIMENTAL
  2. description
    Patients undergo clinical observation.
    intervention Names
    1. Other: Clinical Observation
    label
    Arm II (no treatment)
    type
    OTHER
interventions
  1. arm Group Labels
    1. Arm II (no treatment)
    description
    Patients followed clinically
    name
    Clinical Observation
    other Names
    1. observation
    type
    OTHER
  2. arm Group Labels
    1. Arm I (chemotherapy)
    description
    Given IV
    name
    Docetaxel
    other Names
    1. Docecad
    2. RP56976
    3. Taxotere
    4. Taxotere Injection Concentrate
    type
    DRUG
  3. arm Group Labels
    1. Arm I (chemotherapy)
    description
    Given IV
    name
    Doxorubicin Hydrochloride
    other Names
    1. 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
    2. ADM
    3. Adriacin
    4. Adriamycin
    5. Adriamycin Hydrochloride
    6. Adriamycin PFS
    7. Adriamycin RDF
    8. ADRIAMYCIN, HYDROCHLORIDE
    9. Adriamycine
    10. Adriblastina
    11. Adriblastine
    12. Adrimedac
    type
    DRUG
  4. arm Group Labels
    1. Arm I (chemotherapy)
    description
    Given subcutaneously (SC)
    name
    Filgrastim
    other Names
    1. FILGRASTIM, LICENSE HOLDER UNSPECIFIED
    2. G-CSF
    3. Neupogen
    4. r-metHuG-CSF
    5. Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
    6. rG-CSF
    7. Tevagrastim
    type
    BIOLOGICAL
  5. arm Group Labels
    1. Arm I (chemotherapy)
    description
    Given IV
    name
    Gemcitabine Hydrochloride
    other Names
    1. dFdCyd
    2. Difluorodeoxycytidine Hydrochloride
    3. Gemzar
    4. LY-188011
    5. LY188011
    type
    DRUG
  6. arm Group Labels
    1. Arm I (chemotherapy)
    description
    Given SC
    name
    Pegfilgrastim
    other Names
    1. Filgrastim SD-01
    2. filgrastim-SD/01
    3. Fulphila
    4. HSP-130
    5. Jinyouli
    6. Neulasta
    7. Neulastim
    8. Pegfilgrastim Biosimilar HSP-130
    9. SD-01
    10. SD-01 sustained duration G-CSF
    type
    BIOLOGICAL
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
38
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Analyses will be carried out using proportional hazards models of both survival and recurrence.
    measure
    Univariate and Multi-variable Prognostic Significance of Baseline Clinical, Pathologic, or Demographic Factors
    time Frame
    Up to 5 years
primary Outcomes
  1. description
    The duration of time from study entry to time of death or the date of last contact.
    measure
    Number of Participants Who Experienced Death
    time Frame
    Follow-up every 4 months for 3 years, then every 6 months for 2 years.
secondary Outcomes
  1. measure
    Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
    time Frame
    Approximately 4 years
  2. description
    The duration of time from study entry to time of recurrence or death, whichever occurred first, or the date of last contact.
    measure
    Number of Participants With Recurrence
    time Frame
    Follow-up every 4 months for 3 years, then every 6 months for 2 years.
Full study description
brief Summary
This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.
detailed Description
PRIMARY OBJECTIVES: I. To determine whether overall survival of patients with uterus-limited high-grade leiomyosarcoma is superior among patients assigned to treatment with adjuvant gemcitabine hydrochloride (gemcitabine) plus docetaxel followed by doxorubicin hydrochloride compared to patients assigned to observation. SECONDARY OBJECTIVES: I. To determine whether treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin improves recurrence-free survival of patients with uterus-limited high-grade leiomyosarcoma compared to observation. II. To explore the impact of potential predictors of recurrence or death such as patient age, institution reported tumor size, cervix involvement (yes or no), and mitotic rate. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo computed tomography (CT) and/or magnetic resonance imaging (MRI). Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3. Arm II: Patients undergo clinical observation. After completion of study treatment, patients in both arms are followed up every 4 months for 3 years and then every 6 months for 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e9c8b346de059280ab29
      requested nct id
      NCT01533207
      primary nct id
      NCT01533207
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      payload sha256
      c1e3dfa0ccd374496840b2fc7d208d170468a054d054d1636a9fe5b892022638
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e9c8b346de059280ab29
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01533207
      occurrences
      1. context exact
        NCT01533207
        end
        11
        exact text
        NCT01533207
        start
        0
      offset unit
      unicode_code_points
      query cond
      Uterine Sarcoma
      query disease state id
      ds-uterine-sarcoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-uterine-sarcoma-000.json
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      source json pointer
      /studies/12/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      14c684f24b3a98106ce5f685379e14e3d4f4d81a15bbf8d0b6055f0d2eb18677

    Preserved source evidence · Not medical advice